Pfizer Just Sold a Cancer Drug for the Price of a Nice House

And Pfizer has bigger problems to worry about. The company financed most of the Seagen deal with approximately $31 billion in new debt, which means every dollar spent on development needs to earn its keep quickly. Pfizer projected Seagen-related products would contribute around $3.1 billion in revenue in 2024, ramping to $10 billion by 2030. That's a long runway with a lot of turbulence ahead.

The turbulence has already started. Pfizer has taken billions in write-downs on Seagen programs since early 2025. Its lead ADC candidate, sigvotatug vedotin, failed a Phase 3 trial, prompting HSBC to downgrade the stock in July 2026. Analysts are increasingly skeptical that the Seagen deal will ever pay for itself.

So a non-core, early-stage ADC targeting CD228? That's an easy cut.

Enter Medicus Pharma, the Bargain Hunter

Medicus Pharma is not exactly a household name. The company started life as a Canadian shell company back in 2008 before transforming into a clinical-stage biotech through a reverse takeover in September 2023. It listed on Nasdaq in November 2024 and celebrated with a Nasdaq Opening Bell ceremony in January 2026.

Its existing pipeline is modest: a Phase 2 program called SkinJect for basal cell carcinoma and a long-acting GnRH antagonist called Teverelix for prostate cancer. Adding a clinical-stage ADC from one of the world's largest pharma companies is, to put it mildly, a significant upgrade.

The deal structure tells an interesting story. Beyond the $12 million upfront, Medicus owes Pfizer $15 million in September 2027, plus potential milestones that could exceed $1 billion and royalties on any future sales. Pfizer is also kicking in $2 million in development funding and retains an option to co-fund the program after a pivotal trial starts.

In other words, Pfizer isn't walking away entirely. It's more like a landlord who sold a fixer-upper but kept a clause in the contract that lets them buy back a share if the renovation goes well.

The Rise of Pipeline Recycling

This deal is part of a growing trend in biotech that you might call "pipeline recycling." Big pharma companies regularly acquire huge portfolios, keep the crown jewels, and sell off whatever doesn't fit. For smaller biotechs, it's like shopping at a luxury consignment store: you can get a designer asset at a fraction of retail.

The ADC space is particularly ripe for this kind of arbitrage. One 2025 landscape review found that 130 new ADC candidates entered clinical development that year alone. But many of those programs are being deprioritized or discontinued as competition intensifies. That churn creates a secondary market where companies like Medicus can scoop up assets that bigger players no longer want to fund.

Analysts still love the ADC modality overall, even if specific programs (and specific acquirers) are struggling. The consensus: ADCs remain strategically critical in oncology, but enthusiasm is getting more selective and data-dependent.

The $43 Billion Question

The real story here isn't about Medicus Pharma getting a bargain. It's about whether Pfizer's massive Seagen bet will ever deliver the returns shareholders were promised.

Every asset that leaves Pfizer's pipeline at a discount chips away at the deal's value thesis. Every write-down makes the math harder. Every failed trial makes the 2030 revenue target look more like a wish than a plan.

Pfizer's defenders will point out that the company still has several promising Seagen-derived programs in development, and that portfolio pruning is a normal part of post-acquisition integration. That's fair. But "normal" doesn't mean painless, especially when you're carrying $31 billion in acquisition debt.

For Medicus, the calculus is simpler. The company picked up a clinical-stage oncology drug with no reported safety signals for less than the cost of a beachfront condo in Malibu. If the drug works, the upside is enormous. If it doesn't, they're out $12 million (plus the $15 million installment next year). That's a bet a small biotech can afford to make.

For Pfizer, it's another reminder that buying a pipeline is easy. Making it pay is the hard part.

The MyoKardia Gang Just Pulled Off a $400M Comeback

The team that built MyoKardia (acquired by Bristol-Myers Squibb for $13.1 billion) just took their new cardiac biotech public in a $400 million upsized IPO. Three late-stage drugs, $554 million in prior venture funding, and a stock that popped on day one: Kardigan is either biotech's next blockbuster or its most expensive sequel.